UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 18, 2008

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-19871	94-3078125			
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)			
3155 Porter Drive, Palo Alto, California		94304			
(Address of principal executive offices)		(Zip Code)			
Registrant's telephone number, including area code:		650.475.3100			
	Not Applicable				
Former name or f	ormer address, if changed since last report	:			
k the appropriate box below if the Form 8-K filing is intended to sions:	o simultaneously satisfy the filing obligation	on of the registrant under any of the following			

ſ	1	Written communications	pursuant to	Rule	425 under	the	Securities	Act (17	CFR 230).425)

- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 1.01 Entry into a Material Definitive Agreement.

Effective March 18, 2008, the Company and Progenitor Cell Therapy, LLC ("PCT") amended their existing note purchase agreement to accelerate the date for repayment of the outstanding principal, plus interest, by PCT to June 26, 2008 and to acknowledge that no additional moneys will be lent under the agreement beyond the \$1 million previously advanced by the Company. In return, the Company agreed to relax certain restrictive covenants and exclusivity provisions.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

March 20, 2008 By: Kenneth B. Stratton

Name: Kenneth B. Stratton Title: General Counsel